Elucidation of a novel pathogenomic mechanism using genome-wide long mate-pair sequencing of a congenital t(16;21) in a series of three RUNX1-mutated FPD/AML pedigrees

Leukemia

Volumn 26, Issue 9, 2012, Pages 2151-2154

  Buijs, A ^a   Poot, M ^a   Van Der Crabben, S ^a   Van Der Zwaag, B ^a   Van Binsbergen, E ^a   Van Roosmalen, M J ^a   Tavakoli Yaraki, M ^a   De Weerdt, O ^b   Nieuwenhuis, H K ^a   Van Gijn, M ^a   Kloosterman, W P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SUBSTITUTION; AUTOSOMAL DISORDER; BLOOD ANALYSIS; BLOOD SAMPLING; BONE MARROW; CANCER PATIENT; CASE REPORT; CHILD; EXON; FAMILIAL PLATELET DISORDER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENE MAPPING; GENE MUTATION; GENE REARRANGEMENT; GENETIC ANALYSIS; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; LETTER; MOSAICISM; MYELOID LEUKEMIA; PEDIGREE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGENY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; THROMBOCYTE DISORDER; THROMBOCYTOPENIA; TRISOMY; UNIPARENTAL DISOMY;

CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 21; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; PEDIGREE; TRANSLOCATION, GENETIC;

EID: 84865861592     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.79     Document Type: Letter

References (15)

1. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999; 23: 166-175. (Pubitemid 29455388)
2. Buijs A, Poddighe P, van Wijk R, van Solinge W, Borst E, Verdonck L et al. A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. Blood 2001; 98: 2856-2858.
3. Owen CJ, Toze CL, Koochin A, Forrest DL, Smith CA, Stevens JM et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood 2008; 112: 4639-4645.
4. Jongmans MC, Kuiper RP, Carmichael CL, Wilkins EJ, Dors N, Carmagnac A et al. Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome. Leukemia 2010; 24: 242-246.
5. Shinawi M, Erez A, Shardy DL, Lee B, Naeem R, Weissenberger G et al. Syndromic thrombocytopenia and predisposition to acute myelogenous leukemia caused by constitutional microdeletions on chromosome 21q. Blood 2008; 112: 1042-1047.
6. Beri-Dexheimer M, Latger-Cannard V, Philippe C, Bonnet C, Chambon P, Roth V et al. Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions. Eur J Hum Genet 2008; 16: 1014-1018.
7. van der Crabben S, van Binsbergen E, Ausems M, Poot M, Bierings M, Buijs A. Constitutional RUNX1 deletion presenting as non-syndromic thrombocytopenia with myelodysplasia: 21q22 ITSN1 as a candidate gene in mental retardation. Leuk Res 2010; 34: e8-e12.
8. Owen C. Insights into familial platelet disorder with propensity to myeloid malignancy (FPD/AML). Leuk Res 2010; 34: 141-142.
9. Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene 2004; 23: 4284-4296. (Pubitemid 38765137)
10. Michaud J, Wu F, Osato M, Cottles GM, Yanagida M, Asou N et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood 2002; 99: 1364-1372. (Pubitemid 34547093)
11. Kloosterman WP, Guryev V, van Roosmalen M, Duran KJ, de Bruijn E, Bakker SC et al. Chromothripsis as a mechanism driving complex de novo structural rearrangements in the germline. Hum Mol Genet 2011; 20: 1916-1924.
12. von Goessel H, Jacobs U, Semper S, Krumbholz M, Langer T, Keller T et al. Cluster analysis of genomic ETV6-RUNX1 (TEL-AML1) fusion sites in childhood acute lymphoblastic leukemia. Leuk Res 2009; 33: 1082-1088.
13. Nottingham WT, Jarratt A, Burgess M, Speck CL, Cheng JF, Prabhakar S et al. Runx1-mediated hematopoietic stem-cell emergence is controlled by a Gata/Ets/SCL-regulated enhancer. Blood 2007; 110: 4188-4197. (Pubitemid 351377782)
14. Bee T, Ashley EL, Bickley SR, Jarratt A, Li PS, Sloane-Stanley J et al. The mouse Runx1 +23 hematopoietic stem cell enhancer confers hematopoietic specificity to both Runx1 promoters. Blood 2009; 113: 5121-5124.
15. Liu L, Ishihara K, Ichimura T, Fujita N, Hino S, Tomita S et al. MCAF1/AM is involved in Sp1-mediated maintenance of cancer-associated telomerase activity. J Biol Chem 2009; 284: 5165-5174.